We evaluated them in relation to the available results of prospective clinical trials dedicated to patients with melanoma brain metastases: Checkmate 204, Australian ABC, and COMBI-MB, which mostly included asymptomatic patients and demonstrated that those patients benefit the most from the modern treatment approach of combined immunotherapy or combined BRAF/MEK inhibitor therapy [11,12,13]. The gene discussed is MAP2K7; the disease is melanoma.